Share-based Payment Arrangement, Expense of Amphastar Pharmaceuticals, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Amphastar Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Amphastar Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $6,297,000, a 13% increase year-over-year.
  • Amphastar Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $26,704,000, a 14% increase year-over-year.
  • Amphastar Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $24,368,000, a 20% increase from 2023.
  • Amphastar Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $20,242,000, a 13% increase from 2022.
  • Amphastar Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17,860,000, a 4.4% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Amphastar Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $26,704,000 $6,297,000 +$701,000 +13% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $26,003,000 $6,382,000 +$602,000 +10% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $25,401,000 $8,393,000 +$1,033,000 +14% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $24,368,000 $5,632,000 +$1,010,000 +22% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $23,358,000 $5,596,000 +$952,000 +20% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $22,406,000 $5,780,000 +$915,000 +19% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $21,491,000 $7,360,000 +$1,249,000 +20% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $20,242,000 $4,622,000 +$318,000 +7.4% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $19,924,000 $4,644,000 +$345,000 +8% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $19,579,000 $4,865,000 +$630,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $18,949,000 $6,111,000 +$1,089,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $17,860,000 $4,304,000 +$454,000 +12% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $17,406,000 $4,299,000 +$380,000 +9.7% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $17,026,000 $4,235,000 -$1,849,000 -30% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $18,875,000 $5,022,000 +$188,000 +3.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $18,687,000 $3,850,000 -$483,000 -11% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $19,170,000 $3,919,000 -$451,000 -10% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $19,621,000 $6,084,000 -$429,000 -6.6% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $20,050,000 $4,834,000 -$448,000 -8.5% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $20,498,000 $4,333,000 +$38,000 +0.88% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $20,460,000 $4,370,000 +$76,000 +1.8% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $20,384,000 $6,513,000 +$2,481,000 +62% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $17,903,000 $5,282,000 +$608,000 +13% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $17,295,000 $4,295,000 +$385,000 +9.8% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2022 2021 FY
Q3 2019 $16,910,000 $4,294,000 +$386,000 +9.9% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $16,524,000 $4,032,000 -$164,000 -3.9% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $16,688,000 $4,674,000 +$8,000 +0.17% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $16,680,000 $3,910,000 -$272,000 -6.5% 01 Oct 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
Q3 2018 $16,952,000 $3,908,000 -$248,000 -6% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $17,200,000 $4,196,000 -$102,000 -2.4% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $17,302,000 $4,666,000 +$215,000 +4.8% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $17,087,000 $4,182,000 +$662,000 +19% 01 Oct 2017 31 Dec 2017 10-K 16 Mar 2020 2019 FY
Q3 2017 $16,425,000 $4,156,000 +$601,000 +17% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $15,824,000 $4,298,000 +$100,000 +2.4% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $15,724,000 $4,451,000 +$600,000 +16% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $15,124,000 $3,520,000 +$62,000 +1.8% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2019 2018 FY
Q3 2016 $15,062,000 $3,555,000 +$128,000 +3.7% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $14,934,000 $4,198,000 +$498,000 +13% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $14,436,000 $3,851,000 +$1,621,000 +73% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $12,815,000 $3,458,000 +$859,000 +33% 01 Oct 2015 31 Dec 2015 10-K 14 Mar 2018 2017 FY
Q3 2015 $11,956,000 $3,427,000 +$767,000 +29% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $11,189,000 $3,700,000 +$1,295,000 +54% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $9,894,000 $2,230,000 +$614,000 +38% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $9,280,000 $2,599,000 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
Q3 2014 $2,660,000 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $2,405,000 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $1,616,000 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

Amphastar Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $24,368,000 +$4,126,000 +20% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $20,242,000 +$2,382,000 +13% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $17,860,000 -$827,000 -4.4% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $18,687,000 -$1,811,000 -8.8% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $20,498,000 +$3,203,000 +19% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $17,295,000 +$615,000 +3.7% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2022 2021 FY
2018 $16,680,000 -$407,000 -2.4% 01 Jan 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
2017 $17,087,000 +$1,963,000 +13% 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020 2019 FY
2016 $15,124,000 +$2,309,000 +18% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2019 2018 FY
2015 $12,815,000 +$3,535,000 +38% 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2018 2017 FY
2014 $9,280,000 +$2,245,000 +32% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
2013 $7,035,000 -$390,000 -5.3% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $7,425,000 01 Jan 2012 31 Dec 2012 10-K 26 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.